Mavrilimumab 100 mg

BIOLOGICAL4 trials

Sponsors

MedImmune LLC

Conditions

Rheumatoid Arthritis

Phase 2

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

CompletedNCT01050998

MedImmune LLCRheumatoid Arthritis

Start: 2010-01-05End: 2012-07-27Updated: 2018-06-25

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

CompletedNCT01706926

MedImmune LLCRheumatoid Arthritis

Start: 2012-08-31End: 2014-01-31Updated: 2016-09-27

A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

TerminatedNCT01712399

MedImmune LLCRheumatoid Arthritis

Start: 2013-01-28End: 2015-12-30Updated: 2017-06-01

A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

CompletedNCT01715896

MedImmune LLCRheumatoid Arthritis

Start: 2013-03-31End: 2015-02-28Updated: 2016-10-31

Related Papers

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.

2018-03-3163 citations

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

2017-02-17100 citations